Zepbound prior authorization — and the sleep-apnea shortcut

For weight management, the common criteria are: a BMI of 30 or higher, or 27 or higher with a weight-related condition; documentation of a supervised diet-and-exercise program (often about 90 days); and documented weight loss of at least 5% from baseline to renew coverage. Some plans also require step therapy — for example, trying Wegovy first before approving Zepbound. Separately, if you have obstructive sleep apnea, Zepbound has its own OSA coverage path with different criteria. Your plan's exact rules can vary.

It can be, and this is the single most valuable thing to know about Zepbound coverage. Zepbound is FDA-approved (since December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity — a non-weight-loss medical indication. Because of that, plans (and Medicare) that exclude weight-loss drugs may still cover Zepbound for OSA when it is documented, typically with a sleep study showing an apnea-hypopnea index at or above the threshold (commonly AHI ≥15). If you have sleep apnea, this path can succeed where a weight-loss request would be flatly denied.

On some plans, yes. Several pharmacy benefit managers make Wegovy the preferred weight-loss agent and require a documented Wegovy trial — often 12 to 16 weeks, with either less than 5% weight loss or an intolerance — before they approve Zepbound. This is step therapy. Not every plan does it, so check your specific policy; if your plan requires it, your prescriber documents the Wegovy trial and its outcome to satisfy the step.

For the weight-loss path: current height, weight, and BMI; a qualifying comorbidity if BMI is 27–30; supervised lifestyle-program records (~90 days with dates); your baseline weight at initiation; and step-therapy documentation if your plan requires a Wegovy trial. For the sleep-apnea path: a sleep study documenting moderate-to-severe OSA (commonly AHI ≥15) plus obesity — that is a different, often shorter, documentation set.

Pick the right door. For weight loss: document BMI (and a comorbidity if 27–30), a supervised lifestyle program, and your baseline weight, then have your prescriber submit a complete PA — including the Wegovy trial if your plan requires that step. For sleep apnea: provide the sleep-study results showing moderate-to-severe OSA. If denied, get the reason in writing, ask for a peer-to-peer review, and appeal or request a formulary exception as appropriate.

Not for weight loss — Medicare is barred by law from covering drugs used for weight loss. But because Zepbound has the FDA sleep-apnea indication, Medicare Part D can cover it for moderate-to-severe OSA when documented. Separately, the Medicare GLP-1 Bridge pilot ($50/month, July 2026–December 2027) covers the Zepbound KwikPen for eligible members as a weight-loss drug. So Medicare members have two possible routes: the OSA indication, or the Bridge.

For the weight-loss indication, most plans require documented weight loss of at least 5% from baseline at re-authorization (commonly 4–6 months in) to continue coverage. Make sure your baseline weight was recorded at initiation and that weights are captured consistently — missing or inconsistent baselines are the most common reason renewals fail. If you were approved under the sleep-apnea indication, continuation is generally tied to that condition rather than a weight threshold.